Policy Update
Protecting Patient Access to Insulin Detemir
On January 20, 2026, Members of Congress sent a formal letter to the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) calling attention to the urgent need to protect patient access to insulin detemir (Levemir).
For many people living with diabetes—particularly pregnant women, children, adolescents, athletes, and those with highly insulin-sensitive needs—insulin detemir is not simply one option among many. Its unique clinical characteristics make it essential for maintaining stable blood glucose and avoiding dangerous lows, and for some patients, other long-acting insulins are not safe or effective substitutes.
With insulin detemir no longer available in the United States, patients and clinicians are facing difficult and, in some cases, risky treatment transitions. In their letter, Members of Congress encourage HHS and FDA to explore existing authorities and regulatory pathways that could help preserve access to this clinically distinct insulin, while continuing to uphold the highest standards for safety and quality.
This letter reflects the voices of patients, families, and clinicians across the country who are seeking continuity of care and the ability to use the insulin that works best for their bodies and their lives.